Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the postmarketing setting and to assess anti-JCV serostatus in samples obtained before diagnosis of progressive multifocal leukoencephalopathy (PML). Thi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology Jg. 78; H. 22; S. 1736
Hauptverfasser:	Trampe, A K, Hemmelmann, C, Stroet, A, Haghikia, A, Hellwig, K, Wiendl, H, Goelz, S, Ziegler, A, Gold, R, Chan, A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 29.05.2012
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Viral - blood Clinical Trials as Topic Cohort Studies Cross-Sectional Studies Female Germany - epidemiology Humans Immunosuppressive Agents - therapeutic use JC Virus - immunology Leukoencephalopathy, Progressive Multifocal - diagnosis Leukoencephalopathy, Progressive Multifocal - epidemiology Leukoencephalopathy, Progressive Multifocal - immunology Leukoencephalopathy, Progressive Multifocal - virology Longitudinal Studies Male Middle Aged Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis - immunology Multiple Sclerosis - virology Natalizumab Predictive Value of Tests Retrospective Studies Risk Assessment Risk Factors Single-Blind Method Germany
ISSN:	1526-632X, 1526-632X
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!